Literature DB >> 18086997

The risk of mortality in patients with psoriasis: results from a population-based study.

Joel M Gelfand1, Andrea B Troxel, James D Lewis, Shanu Kohli Kurd, Daniel B Shin, Xingmei Wang, David J Margolis, Brian L Strom.   

Abstract

OBJECTIVE: To determine the risk of mortality in patients with psoriasis.
DESIGN: Cohort study.
SETTING: General practitioners participating in the General Practice Research Database in the United Kingdom, 1987-2002. PATIENTS: Mild psoriasis, defined as any patient with a diagnostic code of psoriasis but no history of systemic therapy; severe psoriasis, any patient with a diagnostic code of psoriasis and a history of systemic therapy consistent with severe psoriasis. The unexposed (control) population was composed of patients with no history of a psoriasis diagnostic code. Control patients were selected in a 5:1 ratio from the same practice and date in practice as the patients with psoriasis. MAIN OUTCOME MEASURE: Hazard ratio (HR) of time to death using Cox proportional hazards models adjusted for age and sex.
RESULTS: There was no overall effect of mild psoriasis on mortality (HR, 1.0; 95% confidence interval [CI], 0.97-1.02), whereas patients with severe psoriasis demonstrated an increased overall mortality risk (HR, 1.5; 95% CI, 1.3-1.7). The association of severe psoriasis with mortality persisted after adjustment for risk factors for mortality (HR, 1.4; 95% CI, 1.3-1.6) and after exclusion of patients with inflammatory arthropathy (HR, 1.5; 95% CI, 1.3-1.8). Male and female patients with severe psoriasis died 3.5 (95% CI, 1.2-5.8) and 4.4 (95% CI, 2.2-6.6) years younger, respectively, than patients without psoriasis (P < .001).
CONCLUSION: Severe but not mild psoriasis is associated with an increased risk of death.

Entities:  

Mesh:

Year:  2007        PMID: 18086997     DOI: 10.1001/archderm.143.12.1493

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  111 in total

Review 1.  Assessing long-term drug safety: lessons (re) learned from raptiva.

Authors:  Nicole M Seminara; Joel M Gelfand
Journal:  Semin Cutan Med Surg       Date:  2010-03

2.  Validity of The Health Improvement Network (THIN) for the study of psoriasis.

Authors:  N M Seminara; K Abuabara; D B Shin; S M Langan; S E Kimmel; D Margolis; A B Troxel; J M Gelfand
Journal:  Br J Dermatol       Date:  2011-02-03       Impact factor: 9.302

Review 3.  Update on the natural history and systemic treatment of psoriasis.

Authors:  Stephen K Richardson; Joel M Gelfand
Journal:  Adv Dermatol       Date:  2008

4.  Diet and weight loss as a treatment for psoriasis.

Authors:  Joel M Gelfand; Katrina Abuabara
Journal:  Arch Dermatol       Date:  2010-05

Review 5.  Is there truly a risk of lymphoma from biologic therapies?

Authors:  Erica Dommasch; Joel M Gelfand
Journal:  Dermatol Ther       Date:  2009 Sep-Oct       Impact factor: 2.851

Review 6.  Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients.

Authors:  Teo Soleymani; Soumya M Reddy; Jeffrey M Cohen; Andrea L Neimann
Journal:  Curr Rheumatol Rep       Date:  2017-11-20       Impact factor: 4.592

Review 7.  The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Erica D Dommasch; Katrina Abuabara; Daniel B Shin; Josephine Nguyen; Andrea B Troxel; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2011-02-18       Impact factor: 11.527

8.  Trends in incidence of adult-onset psoriasis over three decades: a population-based study.

Authors:  Murat Icen; Cynthia S Crowson; Marian T McEvoy; Frank J Dann; Sherine E Gabriel; Hilal Maradit Kremers
Journal:  J Am Acad Dermatol       Date:  2009-03       Impact factor: 11.527

9.  Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis.

Authors:  E D Dommasch; D B Shin; A B Troxel; D J Margolis; J M Gelfand
Journal:  Br J Dermatol       Date:  2009-11-10       Impact factor: 9.302

10.  Incidence of psoriasis in children: a population-based study.

Authors:  Megha M Tollefson; Cynthia S Crowson; Marian T McEvoy; Hilal Maradit Kremers
Journal:  J Am Acad Dermatol       Date:  2009-12-05       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.